It's been a good week for Bicycle Therapeutics plc (NASDAQ:BCYC) shareholders, because the company has just released its latest full-year results, and the shares gained 8.6% to US$23.98. Revenues of US$27m came in 9.7% below estimates, but statutory losses were slightly better than expected, at US$5.08 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

See our latest analysis for Bicycle Therapeutics

Taking into account the latest results, the current consensus from Bicycle Therapeutics' 13 analysts is for revenues of US$27.9m in 2024. This would reflect a satisfactory 3.3% increase on its revenue over the past 12 months. Per-share losses are expected to explode, reaching US$5.32 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$31.5m and losses of US$5.68 per share in 2024. So there's been quite a change-up of views after the recent consensus updates, withthe analysts making a serious cut to their revenue forecasts while also reducing the estimated losses the business will incur.

The consensus price target was broadly unchanged at US$44.89, implying that the business is performing roughly in line with expectations, despite adjustments to both revenue and earnings estimates. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Bicycle Therapeutics, with the most bullish analyst valuing it at US$60.00 and the most bearish at US$30.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. We would highlight that Bicycle Therapeutics' revenue growth is expected to slow, with the forecast 3.3% annualised growth rate until the end of 2024 being well below the historical 21% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 17% per year. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Bicycle Therapeutics.